A Florida woman has filed a new Taxotere lawsuit against Sanofi-Aventis, alleging she continues to suffer from persistent chemotherapy hair loss long after her treatment was over.

The lawsuit alleges that she was not adequately warned that the condition might persist for years after chemotherapy ended and may even be permanent. This is not the first lawsuit filed over persistent chemotherapy hair loss from Taxotere. Many others have also been filed over Sanofi-Aventis’ negligence and failure to warn.

According to the lawsuit, the plaintiff, Andrea N., began taking Taxotere as part of her chemotherapy treatment in April 2014 and continued for several months through August 2014. Of course, Andrea was aware going into chemotherapy that she would likely lose her hair from the treatment—this is the most recognizable side effect of chemotherapy, after all.

However, Andrea claims that she was not informed of the risk of persistent chemotherapy hair loss, which allegedly continues to this day because of her use of Taxotere.

Indeed, more than three years after her chemotherapy treatment ended, Andrea says her persistent chemotherapy hair loss continues.

Andrea filed her persistent chemotherapy hair loss lawsuit on multiple counts, including failure to warn, negligence, fraudulent misrepresentation and concealment, and fraud and deceit, among others. The lawsuit was filed on Jan. 24, 2018, in the U.S. District Court for the Eastern District of Louisiana.

A growing number of cancer patients like Andrea are coming forward with allegations of persistent chemotherapy hair loss, or alopecia, after treatment with Taxotere—even several years down the line.

Background of Taxotere

Taxotere (also known by its generic name, docetaxel) is a widely used chemotherapy treatment manufactured by pharmaceutical giant Sanofi Aventis. Since Taxotere’s approval by the U.S. Food and Drug Administration (FDA) back in 1996, it has become one of the more popular chemotherapy drugs.

But patients claim that Taxotere carries with it a higher risk of persistent chemotherapy hair loss than other options.

Taxotere Persistent Chemotherapy Hair Loss

Hair loss is a common symptom associated with chemotherapy treatment. The majority of cancer patients go into chemotherapy treatment aware that they will likely lose their hair. However, patients generally expect that their hair will grow back once chemotherapy treatment is over.

Unfortunately, a growing number of cancer patients like Andrea are finding the persistent chemotherapy hair loss to be much more permanent in nature than they originally believed.

Filing a Taxotere Lawsuit Over Permanent Chemo Hair Loss

If you or someone you love has suffered from persistent chemotherapy hair loss from Taxotere or another docetaxel medication, you may be able to gain some kind of financial compensation by joining a Taxotere lawsuit.

Filing a Taxotere lawsuit cannot take away the pain and suffering a cancer patient endures, or take away the effects of permanent hair loss, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Persistent Chemotherapy Hair Loss Lawsuit is Case No. 2:18-cv-00726-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.